7月10日 - ** 药物开发商Passage Bio PASG.O股价盘前下跌12%至38美分
** 该公司称 (link) 将进行 1 对 20 的反向拆股，2025 年 7 月 14 日生效
** 该公司表示，股东每持有20股股票，现在将拥有1股股票
** Passage Bio 称，已发行股票数量将从约 6240 万股减少到约 310 万股，股票交易代码仍为 "PASG"。
** PASG目前正在开发治疗罕见遗传性神经退行性疾病的基因疗法。
** 截至上一交易日收盘，PASG 股价累计下跌 22.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.